読み込み中
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
前日終値
$1.41
+$0.07 · +5.22%
日中の時刻はETです。市場データは遅延する場合があります。
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
日中レンジ
現在 $1.41
52週レンジ
現在 $1.41
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
48
適正価値
センチメント
59
まちまち
リスク
68
高リスク
モメンタム
24
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
日中レンジ
現在 $1.41
52週レンジ
現在 $1.41
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 1.9万 USD | 2.4万 USD | 7000 USD | 2.8万 USD | 7.2万 USD |
| 粗利益 | −1.9万 USD | −2.4万 USD | −7000 USD | −2.8万 USD | −7.2万 USD |
| 研究開発 | 680.2万 USD | 2152.9万 USD | 915.8万 USD | 277.8万 USD | 654.6万 USD |
| 販売・一般管理 | 688.7万 USD | 725.6万 USD | 672.8万 USD | 864万 USD | 875.2万 USD |
| 営業費用 | 1368.9万 USD | 2880.9万 USD | 1588.6万 USD | 1962.8万 USD | 1529.8万 USD |
| 受取利息 | 51万 USD | 92万 USD | 46.1万 USD | — | 1.4万 USD |
| 支払利息 | — | — | — | 219.1万 USD | — |
| 減価償却費と償却費 | 1.9万 USD | 2万 USD | 6000 USD | 2万 USD | 4.8万 USD |
| 営業利益 | −1370.8万 USD | −2880.9万 USD | −1588.6万 USD | −1962.8万 USD | −1529.8万 USD |
| 純利益 | −1297.3万 USD | −2759.2万 USD | −1247万 USD | −1396.7万 USD | −1528.4万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2025年12月5日 | 1:11 | — | — |
株式分割 | 2023年12月21日 | 1:8 | — | — |
株式分割 | 2022年9月13日 | 1:30 | — | — |
株式分割 | 2019年12月31日 | 1:25 | — | — |
発効済み 2025年12月5日
1:11
発効済み 2023年12月21日
1:8
発効済み 2022年9月13日
1:30
発効済み 2019年12月31日
1:25
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
